[Form 4] ResMed Inc. Insider Trading Activity

Rhea-AI Filing Summary

ResMed insider trades on 09/02/2025: Chief Financial Officer Brett Sandercock executed both an acquisition and a sale in ResMed common stock under a Rule 10b5-1 plan. He acquired 2,000 shares at $101.64 per share and sold 3,000 shares at $270.77 per share. Following these transactions his beneficial ownership is reported as 87,745 shares. The 2,000-share purchase reflects option-related activity: a grant of 2,000 options with an exercise price of $101.64 exercisable beginning 11/11/2019 and expiring 11/14/2025; options vest one-third per year. The Form 4 indicates the trades were made pursuant to a 10b5-1 trading plan adopted February 19, 2025.

Positive

• Acquisition disclosed: CFO acquired 2,000 shares at $101.64, recorded on the Form 4
• 10b5-1 plan used: Transactions were conducted under a plan adopted February 19, 2025, providing an affirmative defense
• Options disclosed: 2,000 options with $101.64 exercise price and clear exercisable and expiration dates

Negative

• Net decrease in holdings: Beneficial ownership fell from 90,745 to 87,745 shares after a 3,000-share sale at $270.77
• Sell transaction size: Sale of 3,000 shares represents a material individual transaction relative to insider activity though not flagged as company-level material

Insights

Financial Analyst

TL;DR: Officer executed both a purchase and a sale under a 10b5-1 plan; net holdings declined modestly to 87,745 shares.

The Form 4 shows routine insider transactions by the CFO on 09/02/2025: a 2,000-share acquisition at $101.64 and a 3,000-share disposition at $270.77. The acquisition is linked to options covering 2,000 shares with a $101.64 strike exercisable since 11/11/2019 and expiring 11/14/2025. Transactions were conducted under a 10b5-1 plan adopted February 19, 2025, which provides an affirmative defense for pre-specified trades. The net effect is a reduction in beneficial ownership to 87,745 shares; the activity appears procedural rather than a material corporate event.

Corporate Governance Expert

TL;DR: Trades follow a documented 10b5-1 plan and are disclosed promptly via Form 4.

The filing accurately discloses the CFO's transactions and notes the 10b5-1 plan adoption date of February 19, 2025. The Form 4 includes required option detail: strike price, exercisable date, vesting cadence, and expiration. Disclosure appears compliant with Section 16 reporting obligations and shows no indication of undisclosed related-party or indirect ownership interests beyond the direct holdings reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandercock Brett

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD.

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	09/02/2025		M(1)		2,000	A	$101.64	90,745	D
ResMed Common Stock	09/02/2025		S(1)		3,000	D	$270.77	87,745	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$101.64	09/02/2025		M			2,000	11/11/2019(2)	11/14/2025	ResMed Common Stock	2,000	$0	4,000	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted February 19, 2025.

2. Represents date options first become exercisable. Options vest 1/3 per year.

	Brett Sandercock, Chief Financial Officer	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ResMed CFO Brett Sandercock report on Form 4 (RMD)?

The Form 4 reports a 2,000-share acquisition$101.64 and a 3,000-share sale$270.77, both dated 09/02/2025.

Were the trades executed under a trading plan for ResMed (RMD)?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 plan adopted February 19, 2025.

How many ResMed shares does the CFO beneficially own after these transactions?

Following the reported transactions the CFO beneficially owns 87,745 shares.

Does the Form 4 disclose any option grants related to these transactions?

Yes. The filing shows 2,000 options$101.64, exercisable beginning 11/11/2019 and expiring 11/14/2025; options vest one-third per year.

When were the reported transactions executed?

Both the acquisition and the sale are reported with the transaction date 09/02/2025.